In response to the fasting, glycogenolysis and gluconeogenesis are activated. Glucagon, epinephrine and glucocorticoids increase hepatic glucose production in the liver directly or indirectly through the cAMP-PKA signaling pathway (5) . The phosphorylation of CREB at Ser133 by PKA, in turn, recruits co-activators such as CBP, p300 and CRTC2 to CRE containing genes and facilitates hepatic gluconeogenesis. Both glucagon and insulin have been shown to stimulate phosphorylation of CREB at Ser133 (6) , which constitutively occupies the CRE containing promoters in both fasted and fed states (6, 7) . Thus, phosphorylation of CREB at Ser133 is necessary, but is not sufficient for modulating hepatic gluconeogenic gene expression. We have previously reported that insulin and metformin inhibit hepatic glucose production (HGP) by phosphorylating CBP at Ser436, therefore, triggers the disassembly of the CREB-CBP complex (7); furthermore, the phosphorylation of CRTC2 at Ser171 lead to its nuclear exclusion and degradation (6) .
CBP and p300 are closely related proteins that share extensive homology at the amino acid level (~60%), including three cysteine-histidine rich domains (CH1-3), the CREB binding domain (KIX domain), the bromodomain, the HAT (histone acetyltransferase) domain and the SID (steroid receptor co-activator interacting domain) domain (8) (9) (10) . Through these domains, p300 and CBP interact with basal transcription factors and RNA polymerase II as well as a variety of other transcription factors to function as scaffold proteins facilitating interactions among the basal transcription machinery and upstream transcription factors (8) (9) (10) (11) . The HAT activity of p300 and CBP modifies histones leading to chromatin remodeling and transcriptional activation; p300 and CBP also acetylate other proteins such as FXR, SREBP-1, CRTC2 and FOXO1, leading to the changes of genes related to glucose and lipid metabolism (12) (13) (14) (15) . Gene alterations in CBP and p300 cause various diseases, such as Rubinstein-Taybi syndrome and leukemia (8, (16) (17) (18) . Here, we report that the constitutive p300 occupancy on gene promoters is important for gluconeogenesis since it maintains basal hepatic glucose production in the fasted and post-prandial states.
EXPERIMENTAL PROCEDURES
Plasmids and adenoviruses. The expression vectors for wild-type (WT) CBP, CBP mutants and PKA were as described previously (19) . The p300G422S expression vector was generated using site-directed mutagenesis (Stratagene). CH1 domain mutants linked to the Kix domain of CBP and p300 were cloned into the pCMV-AD vector in the same reading frame as the NF-kB (Rel A) transcriptional activation domain (Stratagene). CRE-luciferase reporter vector contains 4 tandem consensus CRE sites upstream of the luciferasecoding region. The Pck1 promoter-luciferase reporter was constructed by cloning the proximal promoter of Pck1 (-490 to +1) into the pGL4 luciferase reporter construct, which contains a CRE site (Promega). The BLOCK-iT adenoviral RNAi expression system (Invitrogen) was used to construct adenoviral shRNA for CBP, p300 and scrambled shRNA as we previously described (7) .
Cell cultures. Lipofectamine 2000 (Invitrogen) was used to transfect equal amounts of plasmids into mouse hepatoma cell lines (H2.35 or Hepa1-6). After 48-hours of transfection, cells were exposed either to 20 nM insulin for 2-4 h or 2 mM metformin overnight. In the two-hybrid assay, 100 ng pFR-Luc, 10-20 ng pFA-CREB (full length) and 10-20 ng pCMV-AD vectors and/or 100ng PKA were transfected.
Glucose production assays. Mouse primary hepatocytes from fed mice (unless otherwise specified) were cultured in six-well plates with William's medium E supplemented with ITS (BD Biosciences) and dexamethasone. Primary hepatocytes were infected 16-24 h after planting with adenoviral shRNAs. After 72 h incubation, cells were washed twice with PBS. Then, medium was replaced with 1 ml of glucose production buffer consisting of glucose-free DMEM supplemented with 20 mM sodium lactate and 2 mM sodium pyruvate or with 0.2 mM 8-bromocAMP. After 5 h incubation, both medium and cells were collected.
Animal experiments. All animal protocols were approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University. For generation of p300G422S knock-in mice, a point mutation in p300 at G422 was introduced using site-directed mutagenesis into the targeting construct; a self-excising ACN cassette was also inserted into an artificially reconstituted BglII site in intron 5. The linearized and purified targeting vector DNA was electroporated into E14 ES (129) cells that were grown in medium supplemented with G418 in order to select for those cells in which integration the targeting vector occurred. Southern blot and the PCR strategy were used to select the ES cells harboring the targeted locus. The targeted embryonic stem cells were injected into blastocysts derived from the mouse strain C57BL/6. The blastocysts were transferred to foster mothers to produce transmitting chimeras. The chimeric male mice with the greatest degree of agouti coat color (~ 90 %) were used to mate with C57BL/6 mice to generate heterozygous mutant p300 mice. Southern blot and PCR analysis were used to determine the genotype of the generated mouse line. The littermates were used to generate WT and mutant homozygous p300 mice.
For hepatic mutant p300 phosphorylation measurement and tolerance tests, mice were injected intraperitoneally (ip) with 1.0 unit/kg insulin, 1.5 g/kg pyruvate or PBS after fasting for the indicated time. Adenoviral shRNA knockdown experiments were conducted 64-72 h after mice were injected with the adenovirus (7) .
Euglycemic-hyperinsulinemic clamp experiment. The clamp experiments for p300 mutant mice and their littermates were conducted at the age of 5-6 months. Surgical catheterizations of the jugular vein were performed with PE-10 tubing. After 3 days of recovery, mice were subjected to 5 h fasting before the clamp procedure previously described (7) . Briefly, a mouse was given 3 uCi bolus [ 3 H]glucose prime followed by a 0.05 uCi/min continuous infusion, and blood samples were collected at 60, 70, 80 min through tail vein nick for measuring basal glucose production. Then, we doubled the [ 3 H]glucose infusion rate, and bolus of insulin was given followed by a 5 mU/kg/min continuous insulin infusion, and glucose levels were measured every 5 min. An infusion of 30% glucose was adjusted to maintain blood glucose at 100-120 mg/dl. Usually, it took 40-60 min to reach a steady blood glucose level after starting the clamp. After reached the steady blood glucose levels, three blood samples were collected for measuring the [ 3 H]glucose. Immunoblot and chromatin immunoprecipitation.
Phospho-S436 CBP antiserum was generated against a phospho-CBP peptide containing amino acids 431-440 of the mouse CBP protein, which contains identical amino acids as those in p300G422S mice in the region of the phosphorylation site. The chromatin immunoprecipitation assay was performed as we previously described (7) .
Statistical Analyses. Statistical significance was calculated with a student's t test and ANOVA test. Significance was accepted at the level of p < 0.05.
RESULTS
The critical role of CBP and p300 in mediating hepatic glucose production and maintaining blood glucose levels. Previous study has shown that the depletion of CBP or p300 significantly decreased ad-CRE-luciferase reporter activity in fasted mice (20) . To examine further whether co-activators CBP and p300 have a similar role in regulating gluconeogenic gene expression, we employed adenoviral shRNAs to knockdown CBP and/or p300 in hepatoma Hepa1-6 cells co-transfected with CBP and p300, and conducted CRELuciferase reporter assays. We found that depletion of either p300 or CBP reduced and that depletion of both proteins abolished PKA stimulated CRE reporter activity (Fig.1a) . The depletion of CBP protein led to an increase in p300 protein and vice versa. We next performed glucose production assays in primary hepatocytes. Depletion of either CBP or p300 decreased cAMP-stimulated glucose production, while depletion both CBP and p300 reduced glucose production even further (Fig. 1b) . The fold induction of PKA or cAMP was still preserved after individual CBP or p300 depletion in these experiments, suggesting that either protein is able to mediate the PKA or cAMP effect (Fig.1a,b) . Furthermore, the depletion of CBP or p300 resulted in decreased mRNA levels of gluconeogenic genes in the liver of 24 h fasted mice (Fig.1c) . To assess further the role of p300 in mediating HGP, we used adenoviral shRNA through tail vein injection to deplete p300 in the liver (Fig.1d) . Depletion of p300 significantly reduced blood glucose levels in both post-prandial and fasting states (Fig.1d) . These data indicate that p300 functions in maintaining blood glucose levels in both fasted and postprandial states.
Constitutive p300 gene promoter occupancy maintains basal HGP due to the lack of a phosphorylation site found in CBP. Since depletion of p300 in the liver led to lower blood glucose levels in post-prandial and fasted states (Fig.1d) , we examined the binding of p300 to hepatic CREs.
Hepatic protein levels of p300, CBP, and CREB remained unchanged in mice during a 24 h fasting period (Supplemental Fig.S2 ). However, fasting increased CBP binding to the Ppargc-1 gene promoter in a chromatin immunoprecipitation (ChIP) assay, reaching maximal binding by 6 h (Fig.2a) and consistent with our previous finding that non-phosphorylated CBP reassembles the CREB co-activator complex (7) . In contrast, the binding of p300 and CREB to the CRE site of the Ppargc-1 gene promoter was unchanged. We then examined hepatic p300 and CBP gene promoter binding in fasted and re-fed mice. In agreement with our previous report, CBP was absent from the Ppargc-1 gene promoter in the liver of re-fed mice (7), while p300 constitutively bound to the CRE site independent of the nutritional state (Fig.2b) . Furthermore, intraperitoneal insulin administration decreased binding of CBP to the CRE site but had no effect on p300 binding to the promoter (Fig.2c ). CREB and p300 did not bind to the proximal region of Gapdh promoter in ChIP assay, demonstrating the specificity of this assay (data not shown).
CBP and p300 are highly homologous proteins and have similar functional domains (Fig.2d , upper panel). Compared to CBP, p300 lacks the insulin phosphorylation site found in CBP due to a one amino acid difference (Fig.2d , lower panel). This amino acid difference has also been proposed to affect the length of the α4 helix of the CH1 (also named TAZ1) domain of these proteins (21) . To gain insight into how the CH1 domain of CBP may affect binding to CREB via the Kix domain, we fused full-length and truncated CH1-Kix domain fragments downstream of a transcriptional activation domain of NF-kB (Rel A) in an expression vector (Fig.2e) . By using these constructs with Gal4-CREB in a two-hybrid assay in Hepa1-6 cells, we found that the CH1 domain (α [1] [2] [3] [4] helix) was completely dispensable for the binding of the CBP Kix domain to CREB (Fig.2f ).
To support this notion, we also deleted the first three α-helices in the CH1 domain of full-length CBP to match a mouse model where CH1 domain deletion was made in the germline (22) . Compared to wild type CBP, the deletion of these α-helices did not affect PKA-stimulated CRE-luciferase reporter activity (Fig.2g, Supplemental Fig.S3a) ; additionally, insulin treatment decreased reporter activity in cells co-transfected with truncated CBP in the presence or absence of PKA (Fig.3a) . These data do not support the conclusion that the first two α-helices of CH1 domain are important for CREB binding (22) .
Since the phosphorylation site of CBP at S436 resides at the end of α4-helix of CH1 domain (Fig.2d,e) , we next asked more specifically whether phosphorylation of this site would affect binding of the Kix activation domain construct to CREB. We found that both insulin and metformin treatment decreased GAL4 reporter activity in cells cotransfected with an activation construct containing an intact Ser436 phosphorylation, but not with a mutated construct ( Fig.3b and Supplemental Fig.S3b ), supporting our previous finding (7). However, p300 lacks this phosphorylation site found in CBP and constitutively binds to CRE site ( Fig.2a-c ). To determine whether the constitutive binding of p300 to CRE site is due to lack of the corresponding phosphorylation site in CBP, we constructed an activation domain vector of p300 bearing an artificial phosphorylation site at Gly422. Using the Gal4-CREB in two-hybrid assay, insulin treatment significantly decreased reporter activity only in cells co-transfected with the construct bearing an artificial phosphorylation site (Fig.3c) . We further compared the effect of co-transfected full-length WT and mutant CBP and p300 expression vectors on either a CRE luciferase reporter in H2.35 cells or a Pck1 promoter in Hepa1-6 cells with or without insulin treatment. Co-transfection of CBPS436A and WT p300 led to greater stimulation of reporter activity when compared with co-transfection of either WT CBP or p300G422S (Fig.3d,e) . Insulin treatment decreased reporter activity in cells co-transfected with WT CBP or p300G422S but not in cells co-transfected with CBPS436A or WT p300. The above data suggest that insulin does not affect WT p300-mediated CREB activation due to the absence of this phosphorylation site.
By using a mutant mouse model containing a putative CBP knock-out allele (23), Bedford et al. showed that these mice had normal glucose metabolism, arguing that CBP is not important in mediating this process (22) . In this mutant mouse model, exon 9 of CBP was floxed; and if this exon is deleted by cell-specific recombination, a frameshift mutation is generated and a new stop codon is introduced in exon 10. The authors did not formally exclude, however, that the first 8 exons (1-607 a.a.) (Fig.2d,e) , and strongly activate reporter activity in CRE-luciferase assay (Fig.3f) , and insulin treatment inhibited the reporter activity (Fig.3g) . Thus, the possible expression of first 8 exons in their CBP knock-out mice may still be able to mediate gluconeogenic gene expression. Interestingly, their CBP knock-out mice also exhibited increased p300 binding to the CRE site, suggesting that p300 may play a compensatory role (22) .
Reconstitution of a phosphorylation site in p300G422S knock-in mice results in lower blood glucose levels in post-prandial state. Having seen that p300 is an important mediator of gluconeogenic gene expression and gluconeogenesis (Fig.1) , and that insulin treatment had no effect on reporter activity when cotransfected with WT p300 (Fig.3c-e ) , we generated a p300G422S knock-in mouse model bearing a reconstituted aPKC phosphorylation site found in CBP (Fig.4a) . P300G422S knock-in mice have similar growth rates, body composition, food consumption levels compared to WT littermates (Fig.4b,c, Supplemental Fig.S4a) , and hepatic protein levels of CREB, p300, and CBP were not different between WT littermates and p300G422S knock-in mice (Supplemental Fig.4b ). P300G422S knock-in mice, however, displayed lower blood glucose levels and lower serum insulin levels in the post-prandial state when compared to WT littermates (Fig.4d,e) , but prolonged fasting led to the disappearance of lower blood glucose levels found in p300G422S mice (Fig.4d) . This relative hypoglycemia in p300G422S knock-in mice was also associated with significantly lower mRNA levels of gluconeogenic enzyme gene in the postprandial state (Fig.4g) . Even though we examined the mRNA levels of Ppargc1 and Pck1, other enzyme(s) in gluconeogenic pathway may be affected in p300G422S knock-in mice as well. P300G422S knock-in mice also exhibited decreased glucose production following injection of pyruvate (Fig. 4h,i) . In a cycloheximide assay, the introduction of a phosphorylation site in p300 did not affect its protein stability (Fig.5a) . Moreover, the levels of mutant p300 protein did not change in different nutritional states (Supplemental Fig.S4b) . The phospho-peptide used to generate the phospho-CBP specific antibody contained the same amino acid sequence found in mutant p300. Therefore, this phospho-CBP antibody should also recognize the mutant p300 site. Since CREB, CBP and p300 could co-exist in the same complex in the liver of fasted mice (Fig.5b) , we used adenoviral shRNA to deplete CBP in the liver of fasted mice to determine whether p300G422S can be phosphorylated. Insulin and metformin treatment phosphorylated hepatic p300G422S in the absence of CBP in mutant mice (Fig.5c) . To confirm further that mutant p300G422S is phosphorylation competent, we overexpressed WT or mutant p300 in CBP depleted hepatoma cells (Hepa1-6) and treated with metformin.
Metformin treatment only phosphorylated mutant p300, not WT p300 (Fig.5d) . The above data clearly demonstrate that mutant p300 is phosphorylation competent. Consistent with this result, we observed increased phosphorylation of CBP and p300 in the liver of p300G422S knock-in mice when compared to control mice (Fig.5e) . Additionally, phosphorylation of CBP and p300 persisted for a longer time in the p300G422S knock-in mice than in WT controls during a fasting experiment (Fig.5f ). The time course for CBP and p300 dephosphorylation corresponded to the disappearance of lower blood glucose levels in p300G422S knockin versus WT mice (Fig.4d,5f ).
The binding of p300 to the CRE site is independent of the nutritional state (Fig.2a-c) , and p300 lacks an aPKC phosphorylation site found in CBP, we aimed to determine whether insulin treatment would lead to dissociation of p300 from the CRE sites of the Ppargc1 and Pck1 gene promoter in mutant mice. Indeed, unlike WT p300, mutant p300 was absent from the Ppargc-1 promoter (Fig.5g, left panel) and Pck1 promoter (data not shown) after insulin administration. We assessed the binding of p300 and CBP on the CRE site of G6pc gene promoter, and had a similar pattern of changes as on the CRE sites of Ppargc1 and Pck1 gene promoter (Fig.5g, right panel) . Mutant p300 was absent from the CRE site of the Ppargc-1 promoter in the liver of re-fed mice (Fig.5h) . To support further the notion that the introduction of a phosphorylation site in p300 resulted in the decreased hepatic glucose production, we conducted glucose production assays in primary hepatocytes. Hepatocytes from p300G422S knock-in mice produced significantly less glucose than hepatocytes from control mice in both basal and cAMP treatment groups (Fig.6a) . Primary hepatocytes from 24 h fasted WT and p300G422S knock-in mice produced an equal amount of glucose after 24 h of culture in serum starvation conditions (Fig.6b) , which further substantiates the results that prolonged fasting led to the disappearance of the lower blood glucose levels in p300G422S knock-in mice. In agreement with the notion that fasting led to the disappearance of lower blood glucose levels in p300G422S knockin mice (Fig.4d) , basal glucose disposal rates in the euglycemic-hyperinsulinemic clamp did not differ between p300 mutant mice and littermate control mice after 5 h of fasting (Fig.6c) . During the clamp experiment, both glucose disposal and glucose infusion rates were significantly increased in p300G422S knock-in mice (Fig.6d) , demonstrating enhanced insulin sensitivity in the liver as well as peripheral tissues. A major cause for enhanced sensitivity was hepatic, since glucose production was completely suppressed in p300G422S knock-in mice but not WT littermate mice at the insulin concentration used in this study (Fig.6d, right) .
DISCUSSION
An unexplained observation in humans has been that gluconeogenesis is not completely suppressed even in the presence of excess insulin (24-27). We and others have shown that CREB coactivators play critical roles in maintaining fasting blood levels ( Fig.1) (7,19,20 ). In the current study, we found that depletion of hepatic p300 resulted in decreased hepatic mRNA levels of gluconeogenic genes, lower blood glucose levels in the postprandial state and fasting stages (Fig.1) . These data suggest that p300 is an important co-activator in regulating gluconeogenesis. CBP and p300 are closely related proteins, and one might predict that they would have similar biological function at the CRE site. Alignment of the amino acid sequence of CBP and p300, however, reveals that S436 in CBP corresponds to G422 in p300, indicating that p300 is not phosphorylated at this site (Fig.2d) . As the phosphorylation of CBP at S436 leads to its dissociation from the CRE site of genes important for gluconeogenesis, the lack of phosphorylation at G422 in p300 may lead to constitutive occupancy of p300 on the CRE of target genes. Indeed, p300 constitutively binds to the CRE site, such as Ppargc1 gene promoter in both the fasted and refed states (Fig.2a,b) . On the other hand, mutant p300 is absent from the CRE site in the re-fed state or after insulin treatment in p300G422S knock-in mice (Fig.5g,h ).
Since insulin phosphorylation of CBP and p300 in p300G422S knock-in mice persisted for a longer time in mutant mice (Fig.5f) , we conducted pyruvate tolerance tests at different fasting time points to evaluate the role of this phosphorylation event in regulating gluconeogenesis. In the presence of significant amount of phosphorylated CBP/p300 (3 h fasting), mutant mice produced less glucose than WT control mice during the entire experiment; in contrast, in the absence of phosphorylated CBP/p300 (12 h fasting), mutant mice produced equal amounts of glucose over the first 60 min of the test (Fig.4h,i) . We suggest that the reduced glucose production in the latter half of pyruvate tolerance test in p300G422S knock-in mice after 12 h of fasting is due to subsequent secretion of insulin and enhanced inhibition of gluconeogenesis in these mice. Moreover, depletion of hepatic p300 led to lower blood glucose levels in the fasted state (Fig.1d) , while the lower blood glucose levels disappeared in p300G422S knock-in mice after prolonged fasting (Fig.4d ) because of the de-phosphorylation of mutant p300 (Fig.5f) . In other words, the phosphorylation of CBP and p300 in p300G422S knock-in mice resulted in dissociation of both co-activators from gluconeogenic genes and suppression of gluconeogenic gene expression in the post-prandial state, leading to lower blood glucose levels. Although the p300G422S knock-in mice harbor an artificial phosphorylation found in CBP, the characterization of this mouse model proves the importance of non-phosphorylated p300 in driving hepatic gluconeogenesis. Hepatic gluconeogenesis during the post-prandial and fed states has important implications for converting gluconeogenic precursors, such as lactate, fructose, and amino acids delivered from gastrointestinal track and other tissues, into glucose that can be stored as glycogen or released into blood as glucose; especially when consuming high protein diet.
CREB co-activators have a cooperative effect in regulating HGP. In the fasting state, the dephosphorylation of CBP and CRTC2 by glucagon stimulates the association of these two co-activators to CREB (7, 20) . Moreover, the de-phosphorylation of p300 at S89 and CBP at S78 in the fasting state by guest on http://www.jbc.org/ Downloaded from results in the activation of their HAT activity (20, 28) . The acetylation of CRTC2 by the HAT of p300 and CBP, in turn, increases the protein stability of CRTC2 and inhibits its nuclear exclusion. Cumulatively, p300, CBP, and CRTC2 work together to mediate gluconeogenic gene expression and maintain hepatic gluconeogenesis in the fasting state. In the fed state, insulin suppresses HGP in part through the phosphorylation of CBP at S436. This phosphorylation event leads to the disassembly of CBP and CRTC2 from the CREB complex. Furthermore, the phosphorylation of p300 at S79 and CBP at S78 by insulin decreases their HAT activity (20, 28) as well as the acetylation of CRTC2, and facilitates the nuclear exclusion and degradation of CRTC2 in the cytoplasm (20) . We previously reported that the activation of AMPK by metformin phosphorylates CBP at S436 via aPKCι/λ (7). A later study showed that the activation of AMPK also results in the phosphorylation of p300 at S89 through aPKCι/λ (29).
Together, insulin and metformin phosphorylate CBP at S436 and disassemble CBP and CRTC2 from CREB. In addition, the phosphorylation of p300 at S89 and CBP at S78 decreases their HAT activity and increases the degradation of CRTC2. We propose that these phosphorylation events are important for the suppression of HGP. 
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